SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia

N/ACompletedNCT02201134

University Hospital, Clermont-Ferrand20 enrolled

Overview

Studying the feasibility of an initial sedation with inhalated sevoflurane during therapeutic hypothermia of cardiac arrests resuscitated patients.

Prospective clinical study in ICU with ventilated patients sedated with sevoflurane using the Mirus® and Anaconda® , establishing the feasibility of an initial sedation of patients resuscitated from cardiac arrest and treated with therapeutic hypothermia.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cardiac Arrest Therapeutic Hypothermia

Interventions

sevofluraneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * -Adult patients ventilated requiring therapeutic hypothermia in ICU * Stable respiratory and hemodynamic conditions * Epinephrine and norepinephrine infusion rate \< 1,5 g/kg/min * Consent of patients or family * Arterial line * Patients resuscitated after cardiac arrest * No Flow \< 10 min * Low Flow \< 20 min * Neutropenia \< 1 G/L * Post traumatic cardiac arrest * Contraindication of halogenated anesthesics * Extra corporeal life support or intra aortic balloon pump Exclusion Criteria: * -Pregnant woman * Hemodynamic instability * Brain death defined by the disappearance of brain stem reflexes

Locations (1)

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Outcomes

Primary Outcomes

Determination of the feasibility of a sedation with inhalated sevoflurane in cardiac arrest resuscitated patients

The feasibility is evaluated by the number of side effects due to treatment until discharge from hospital.

Time frame: at day 1

Secondary Outcomes

Determination of neurological prognostic of patients at ICU and hospital discharge

Time frame: at day 1

Determination of systemic complications and organ failures during hospitalisation

Time frame: at day 1

Evaluation of systemic inflammation and evolution with cytokines

Time frame: at day 1

Evaluation of markers specific of brain ischemia (S100 protein and neuron-specific enolase)

at 3 times: before starting sevoflurane sedation, 24 hours, 48 hours and 72 hours after starting sevoflurane sedation.

Time frame: at day 1

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.